We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

212 hedge funds and large institutions have $3.27B invested in Amicus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 67 increasing their positions, 78 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more call options, than puts

Call options by funds: $11.9M | Put options by funds: $3.45M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more capital invested

Capital invested by funds: $2.81B → $3.27B (+$457M)

0.57% more ownership

Funds ownership: 108.36%108.94% (+0.57%)

4% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 27

2% less funds holding

Funds holding: 217212 (-5)

14% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 78

Holders
212
Holders Change
-5
Holders Change %
-2.3%
% of All Funds
3.57%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
26
Increased
67
Reduced
78
Closed
27
Calls
$11.9M
Puts
$3.45M
Net Calls
+$8.47M
Net Calls Change
+$7.47M

FOLD Hedge Fund Activity: Q2 2022 in Review

212 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2022, worth a combined $3.27B — up 16% from $2.81B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of FOLD and 26 opened new positions — a net loss of 1 holder — while 78 trimmed existing stakes and 67 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $51.9M. The largest seller was Wellington Management Group, cutting an estimated $128M.

  • 212 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2022, down from 217 in Q1 2022.
  • Funds reported $3.27B of Amicus Therapeutics stock for Q2 2022, up 16% quarter-over-quarter.
  • 26 funds opened new Amicus Therapeutics positions in Q2 2022 and 27 closed out, a net change of -1 holder.
  • The largest Amicus Therapeutics buyer in Q2 2022 was Avoro Capital Advisors, an estimated $51.9M added.
  • The largest Amicus Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $128M sold.

Based on aggregated 13F filings for Q2 2022.